Manufacturing

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

Articles

The companies plan on targeting the production of abundant, low-cost messenger RNA from C1-cells.

Dyadic and bYoRNA Collaborate on Production of mRNA

Chris Spivey is the editorial director of 

Videos

Experts discuss the promise of personalized cancer vaccines through the inherent nimbleness of mRNA platform.

Miniaturing Personalized Cancer Vaccines Through mRNA

mRNA may be a modality whose chief advances are yet to come.  

New Magic from mRNA

EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically.

EMA Aims to Develop Guideline for mRNA Vaccines

The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.

Biosynth Acquires Celares for Growing Conjugate Vaccine Market

Grant Playter is the Assistant Editor for 

The new excipients manufacturing facility is expected to be completed in 2025.

Croda Pharma Breaks Ground on Excipients Manufacturing Facility

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.

Transduction for AAV with Sean Hart

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration. 

mRNA Global Alliance Tests the Waters at BIO

Feliza Mirasol is the science editor for 

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

invoX Pharma Invests in pHion Therapeutics to Develop Next-Generation mRNA Vaccines

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Vaccine Development and Manufacturing